About the Authors
- Tram T. Tran
-
* E-mail: Tram.Tran@cshs.org
Affiliation Liver Disease and Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, United States of America
- Stuart C. Gordon
-
Affiliation Division of Hepatology, Henry Ford Hospital, Detroit, Michigan, United States of America
- Scott Fung
-
Affiliation Department of Medicine, University of Toronto, Toronto, Canada
- Phillip Dinh
-
Affiliation Gilead Sciences, Foster City, California, United States of America
- Leland Yee
-
Affiliation Gilead Sciences, Foster City, California, United States of America
- Eduardo Bruno Martins
-
Affiliation Gilead Sciences, Foster City, California, United States of America
- Maria Buti
-
Affiliation Department of Hepatology, Hospital General Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain
- Patrick Marcellin
-
Affiliation Department of Hepatologie, University of Paris, Paris, France
Competing Interests
The authors have read the journal's policy and the authors of this manuscript have the following competing interests: SG has received grant/research support from AbbVie pharmaceuticals, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences Ltd, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, Novartis and Vertex; acted as a consultant for, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences Ltd, GlaxoSmithKline, Novartis and Vertex Pharmaceuticals; and serves on the data monitoring board for Tibotex-Janssen. SF has acted as a consultant, advisor and speaker for Gilead Sciences Ltd and as an advisor and speaker for Merck and Vertex Pharmaceuticals. PD is an employee and stock holder of Gilead Sciences Ltd. LY is an employee and stock holder of Gilead Sciences Ltd. EBM is an employee and stock holder of Gilead Sciences Ltd. MB acts an advisor for Gilead Sciences Ltd, Bristol-Myers Squibb and Novartis. PM has worked with Bristol-Myers Squibb, Gilead Sciences Ltd, Janssen-Tibotec, Merck, Novartis, Roche Pharmaceuticals and Vertex Pharmaceuticals. He has also acted as an investigator for Boehringer Ingelheim and Pfizer, an investigator and expert for Abbott and acted as an investigator and received grant support from Alios BioPharma. TT has no conflicts of interest. The affiliation for Dr Gordon has been amended to ‘Henry Ford Hospital’. This is not a commercial company. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: TT LY EBM. Analyzed the data: TT SG SF LY EBM MB PM. Contributed reagents/materials/analysis tools: TT SG SF PD LY EBM MB PM. Wrote the paper: TT SG SF PD LY EBM MB PM. Approval of final version for publication: TT SG SF PD LY EBM MB PM.